Rekombinanter TNF alpha (Adalimumab Biosimilar) Antikörper

Produktnummer ABIN7200655

Dieses Anti-TNF alpha (Adalimumab Biosimilar)-Antikörper ist ein Maus Monoklonal-Antikörper zur Detektion von TNF alpha (Adalimumab Biosimilar) in FACS und in vivo. Geeignet für Human.

Kurzübersicht für Rekombinanter TNF alpha (Adalimumab Biosimilar) Antikörper (ABIN7200655)

Target: TNF alpha (Adalimumab Biosimilar)

Antikörpertyp: Recombinant Antibody

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser TNF alpha (Adalimumab Biosimilar) Antikörper ist unkonjugiert

Applikation: Flow Cytometry (FACS), In vivo Studies (in vivo)

Klon: D2E7

Produktdetails anti-TNF alpha (Adalimumab Biosimilar) Antikörper

Verwendungszweck: Adalimumab Biosimilar, TNF alpha Monoclonal Antibody

Spezifität: The monoclonal antibody adalimumab biosimilar specifically binds to the human TNF alpha.

Produktmerkmale: Recombinant Humanized IgG1 Monoclonal Antibody.

Aufreinigung: Protein A affinity column

Reinheit: > 95% by SDS-PAGE under reducing conditions and HPLC.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1 EU per 1 mg of the protein by the LAL method.

Immunogen: The monoclonal antibody adalimumab biosimilar was produced in the adalimumab biosimilar CHO stable cell line.

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by adalimumab.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Konservierungsmittel: Without preservative

Handhabung: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Haltbarkeit: 12 months

Details zu TNF alpha (Adalimumab Biosimilar)

Target: TNF alpha (Adalimumab Biosimilar)

Substanzklasse: Biosimilar

Hintergrund: Adalimumab, the first fully human monoclonal antibody drug approved by FDA, binds to TNFα, inactivates TNF receptors, and downregulates the inflammatory reactions associated with a variety of autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic psoriasis and juvenile idiopathic arthritis.

Mainly produced by activated macrophages (M1), Tumor necrosis factor (TNF, cachexin, cachectin, tumor necrosis factor alpha, TNFα) plays important roles in the regulation of immune cells. As a member of a group of cytokines that stimulate the acute phase reaction, TNF is involved in systemic inflammation and able to induce fever, apoptotic cell death, cachexia, inflammation, and to inhibit tumorigenesis and viral replication and respond to sepsis via IL1 & IL6 producing cells. Dysregulation of TNF expression could have serious impact in a variety of human diseases including Alzheimer's disease, cancer, major depression and inflammatory bowel disease.